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Abstract
Background/Aims: To investigate the relation between skel-
etal muscle measurements (muscle mass, radiation attenua-
tion, and sarcopenic obesity), postoperative morbidity, and 
survival after treatment of locally advanced rectal cancer. 
Methods: This explorative retrospective study identified 99 
consecutive patients who underwent neoadjuvant chemora-
diation and surgery between January 2007 and May 2012. 
Skeletal muscle mass was measured as total psoas area and 
total abdominal muscle area (TAMA) at 3 anatomical levels 
using the patient’s preoperative computed tomography 
scan. Radiation attenuation was measured using correspond-
ing mean Hounsfield units for TAMA. Sarcopenic obesity was 
defined as body mass index above 25 kg·m–2 combined 
with skeletal muscle mass index below the sex-specific me-
dian. Postoperative complications were graded by using the 
 Clavien-Dindo classification. Results: Twenty-five patients 
(25.3%) developed a grade 3–5 complication. Lower radia-
tion attenuation was independently associated with overall 
(p = 0.003) and grade 3–5 complications (p = 0.002). Sarcope-
nic obesity was associated with overall complications (all p < 
0.05). Skeletal muscle measurements and survival were not 
significantly related. Conclusion: Radiation attenuation was 
associated with overall and grade 3–5 postoperative morbid-
ity after neoadjuvant chemoradiation and non-laparoscopic 
resection for rectal cancer. Sarcopenic obesity was associated 
with overall complications. © 2018 S. Karger AG, Basel
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Introduction
Treatment of locally advanced rectal cancer consists 
of administration of neoadjuvant chemoradiation fol-
lowed by surgery [1]; this treatment method however re-
sults in 40% postoperative complication rate [2, 3]. There 
is increasing evidence that sarcopenia (indicated by low 
skeletal muscle mass, assessed by measurement of mus-
cle cross-sectional area most often using the computed 
tomography [CT] scan) is associated with poor clinical 
outcomes. Sarcopenia is associated with increased infec-
tious complications, prolonged hospital stay, and de-
creased survival rates following colorectal resection and 
hepatic resection for colorectal liver metastases [4, 5]. 
There is also strong evidence to suggest that obesity is a 
significant risk factor for wound and stoma site compli-
cations after colorectal surgery [6]. Combination of sar-
copenia and obesity may result in even worse outcomes, 
since it combines the health risks of obesity and depleted 
lean muscle mass [7]. Sarcopenic obesity is associated 
with reduced functional status and survival in patients 
with solid tumors of respiratory and gastrointestinal 
tracts [7]. In patients undergoing liver resection for 
colorectal liver metastasis, sarcopenic obesity was associ-
ated with an increased risk of severe postoperative com-
plications compared with patients who did not have sar-
copenia [8].
Timely identification of preoperative risk factors for 
adverse postoperative outcome will help patients and cli-
nicians with treatment decisions, and with the selection 
of patients who might have a therapeutic window that 
leaves room for preoperative improvement of their func-
tional health status known to protect from postoperative 
side effects [9, 10]. The aim of this explorative study was 
to investigate the relation between skeletal muscle mass, 
radiation attenuation (expressed in mean Hounsfield 
Units [HU] for total abdominal muscle area [TAMA]) 
and sarcopenic obesity, and postoperative morbidity and 
survival after the administration of neoadjuvant chemo-
radiation followed by non-laparoscopic resection for rec-
tal cancer. 
Method
Patients
A retrospective study was performed including all consecutive 
patients with locally advanced rectal cancer who were treated with 
chemoradiation and surgery at our institute between January 2007 
and May 2012. This is the same population dataset that we used in 
a previous article [11]. In the current study, however, we added 
data of patients’ skeletal muscle mass, radiation attenuation, sar-
copenic obesity, and survival.
Patients were included in the study if they had locally ad-
vanced rectal cancer (defined as a clinical T4 tumor or T3 tumor 
with a threatened circumferential margin (CRM ≤1 mm) and/or 
cN2 disease [1]) that was histologically proven with a colonos-
copy and biopsy. Patients were excluded if the preoperative ab-
dominal CT scan was missing or if the abdominal CT scan was of 
poor quality.
Neoadjuvant Chemoradiation and Surgery
Patients underwent a 5-week protocol of concomitant chemo-
therapy (825 mg·m–2 capecitabine twice daily) and 3D-conformal 
radiotherapy (50 Gy in 25 fractions). Operations were carried out 
by experienced colorectal surgeons according to the total mesorec-
tal excision principle and consisted of abdominoperineal resec-
tion, low anterior resection (LAR), or rectal resection with defini-
tive colostomy (Hartmann procedure). The considered optimal 
interval between chemoradiation and surgery in 2007–2010 was 6 
to 8 weeks, from 2010–2011 it was 8 to 10 weeks, and since 2012, 
it was 10 to 12 weeks.
Outcome Variables
The baseline characteristics included are age (divided in 
4  groups based on quartiles), sex, body height, body mass, 
 American Society of Anesthesiologists (ASA) score (I-IV), 
Charlson comorbidity score, smoking, clinical TNM stage, neo-
adjuvant chemoradiation regimen, symptoms of obstruction re-
quiring fecal diversion before rectal surgery, interval between the 
end of chemoradiation and resection, complications of chemo-
radiation, type of surgery, diverting stoma (only for patients un-
dergoing LAR), operation time, estimated blood loss, blood 
transfusion intra- or postoperative, pretreatment tumor distance 
from the anal verge, length of hospital stay, postoperative surgi-
cal and general complications, readmission rate, mortality, 
pathologic tumor response, pathologic TNM stage, complete-
ness of surgical excision (R stage), carcinoembryonic antigen 
(CEA) level before neoadjuvant chemoradiation, preoperative 
hemoglobin (Hb), skeletal muscle mass, radiation attenuation, 
and sarcopenic obesity. 
Prespecified definitions were used to score postoperative surgi-
cal complications (until 6 months after surgery) [11]. Complica-
tions were graded by using the Clavien-Dindo classification (grade 
1–5) [12, 13]. An overall complication is a grade 1–5 complication 
and a grade 3–5 complication is a severe complication. General 
complications were divided in cardiovascular, pulmonary, renal, 
or neurological complications.
Survival was defined as overall survival, measured in months 
from the day of surgery, with a follow-up of 3 years. The electron-
ic patient record system was searched for date of death and/or the 
general practitioner was contacted.
Muscle Mass Measurements and Definitions
Preoperative CT scans were imported in TeraRecon (Ter-
aRecon Aquarius; TeraRecon, USA). Skeletal muscle mass was 
exploratively measured at 3 levels because in the literature these 
different levels are used [8, 14, 15]: cross-sections at the third 
lumbar vertebra (L3) where both transverse processes were 
 visible, and at both the superior and inferior border of the 
fourth  lumbar vertebra (L4). At each level, the cross-sectional 
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areas (cm2) of total psoas area (TPA) and TAMA, and skeletal 
muscle radiation attenuation (mean HU of TAMA) were mea-
sured. TPA was measured by manually tracing and adding left 
and right psoas area. TAMA was manually detected and a 
threshold of –29 to +150 HU was applied to this region to dis-
criminate between skeletal muscle and other tissues [16]. Muscle 
area and average HU were then calculated automatically. Muscle 
areas were normalized for the patient’s body height to calculate 
the muscle index for TPA and TAMA in cm2·m–2. A lower HU 
value was considered to be related to a poorer overall skeletal 
muscle radiation attenuation, since lower HU values correspond 
with fatty infiltration of muscle (myosteatosis) [17]. The inves-
tigator who performed the measurements (FdG) was blinded for 
postoperative outcome. In the literature, the measurement of 
cross-sectional muscle area has shown to have a low level of in-
ter-observer variability [18, 19]; however, their muscle measure-
ment methodology differed from the one we followed in our 
study.
Sarcopenia was defined as skeletal muscle mass index (TPA or 
TAMA at each level) below the median, calculated for males and 
females separately (sex specific cut-off value) [20]. Sarcopenic obe-
sity was defined as body mass index (BMI) above 25 kg·m–2 com-
bined with skeletal muscle mass index, TPA, or TAMA, below the 
sex-specific median [20, 21].
Statistical Analysis
Data were analyzed with the Statistical Package for the Social 
Sciences for Windows (version 22.0; IBM, SPSS Inc., Chicago, IL, 
USA). Data are presented as mean and standard deviation for 
continuous normally distributed variables as checked with histo-
grams. For continuous nonparametric variables, median and 
range were presented. Univariate associations between skeletal 
muscle mass measurements (TPA, TAMA, and radiation attenu-
ation), sarcopenia, and sarcopenic obesity with overall and grade 
3–5 postoperative complications were evaluated for significance, 
using Fisher exact test or chi2 test for categorical variables and 
independent t test (if normally distributed) or Mann-Whitney U 
test for continuous variables. Possible confounders (see baseline 
characteristics above) were first tested for association with over-
all and grade 3–5 postoperative complications. In case they were 
associated with overall or grade 3–5 postoperative complications 
(p < 0.150), they were tested for association with the skeletal mus-
cle mass measurements (TPA, TAMA, and radiation attenua-
tion), sarcopenia, and sarcopenic obesity (p < 0.150). The asso-
ciations between skeletal muscle mass measurements (TPA, 
TAMA, and radiation attenuation), sarcopenia, and sarcopenic 
obesity with overall and grade 3–5 postoperative complications 
were corrected for the remaining potential confounders in a step-
wise forward multivariate logistic regression analysis. In case of 
multicollinearity between variables, the variable that produced 
the best model fit (based on the –2 log likelihood) was included 
in the model. Kaplan-Meier estimates and Cox regression analy-
ses were used to assess the association between sarcopenia and 
sarcopenic obesity with overall survival. All baseline characteris-
tics that were associated with either sarcopenia or sarcopenic 
obesity (p < 0.150) were tested for an association with overall 
survival. The variables that were also associated with survival 
were taken into account in the stepwise forward multivariate Cox 
regression analyses. Statistical significance was determined at p < 
0.05.
Results
We identified 105 patients with locally advanced rectal 
cancer who underwent neoadjuvant chemoradiation be-
tween January 2007 and May 2012. After exclusion of 
6  patients (patients with disease progression, extensive 
comorbidity, or unresectable tumors), resection of the tu-
mor was performed in 99 patients (96.1%, of which 53, 
53.5%, males), with a median age of 66 (range 40–81) 
years. Sixty-four patients (64.6%) were overweight 
(BMI ≥25). Eleven patients (11.1%) had a BMI 30–35, and 
6 patients (6.1%) had a BMI ≥35. Median (range) muscle 
index for TAMA at L3 was 52.2 (37.0–70.9) cm2·m–2 in 
men and 39.9 (30.2–75.4) cm2·m–2 in women. We were 
able to retrieve all data of all consecutive patients, except 
body height and/or body mass (n = 3, 3.0%), operation 
time (n = 2, 2.0%), the CEA level before neoadjuvant 
chemoradiation (n = 33, 33.3%), and in 4 patients (4.0%), 
the skeletal muscle mass/quality could not be measured 
on one or more levels because of vertebral screws (n = 1, 
1.0%), poor quality of the CT scan (n = 1, 1.0%), or the 
area of interest was not completely visible on CT scan (n = 
2, 2.0%). In 2 (2.0%) additional patients, the skeletal mus-
cle mass could not be measured because their body height 
was unknown. 
Of the 99 patients that underwent resection, 68 pa-
tients (68.7%) had an overall postoperative complication, 
of which 43 patients (43.4%) had a grade 1–2 complica-
tion and 25 patients (25.3%) a grade 3–5 (severe) com-
plication. An anastomotic leakage was seen in 2 of 18 pa-
tients undergoing LAR, a sepsis was seen in 6 of the 
99 patients (6.1%), and an abdominal wound complica-
tion in 17 of the 99 patients (17.2%). The mortality rate 
was 2.0% (2 patients). A complete overview of all postop-
erative complications can be found in Table 3 of our 
 previous study [11] or in online supplementary file 1 
(for  all online suppl. material, see www.karger.com/
doi/10.1159/000490069). The median follow-up after 
surgery was 32.9 months (interquartile range 19.4–
51.1 months). In the univariate relation between demo-
graphic and clinical variables and overall postoperative 
complications, a younger age (p = 0.017), an intra- or 
postoperative blood transfusion (p = 0.021), and a longer 
operation time (p = 0.093) were associated with postop-
erative complications (p < 0.150). In the univariate rela-
tion between demographic and clinical variables and 
grade 3–5 postoperative complications, male sex (p  = 
0.032), a higher Charlson comorbidity score (p = 0.134), 
a lower CEA score before chemoradiation (p = 0.082), 
ypT stage (p = 0.092), and an intra-or postoperative 
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blood transfusion (p = 0.004) were associated with grade 
3–5 postoperative complications (p < 0.150). A complete 
overview of these results can be found in Table 4 of our 
previous article [11] or in online supplementary file 2. An 
intra- or postoperative blood transfusion was not taken 
into account as a confounder in the multivariate analy-
sis  since the necessity of intra- or postoperative blood 
transfusion could be an intermediary factor between 
skeletal muscle mass and postoperative complications 
(e.g., patients could have had a blood transfusion because 
of a postoperative complication, for example, due to 
bleeding). 
Postoperative Morbidity and Skeletal Muscle  
Mass/Quality
Skeletal muscle mass (TPA and TAMA) was not sig-
nificantly associated with overall or grade 3–5 complica-
tions. In the univariate analysis, a lower skeletal muscle 
radiation attenuation at all 3 measurement levels was sig-
nificantly associated with overall and grade 3–5 compli-
cations (Table 1). TPA at L4 superior and L4 inferior were 
associated (p < 0.150) with grade 3–5 complications and 
were therefore also assessed in the multivariate analysis 
for grade 3–5 complications. Due to multicollinearity be-
tween radiation attenuation measurements (L3, L4 infe-
rior, and L4 superior level) and between TPA measure-
ments (L4 inferior and L4 superior), the variable of radia-
tion attenuation and TPA with the best model fit was 
included in the multivariate logistic regression analysis 
(radiation attenuation at L3 for both overall and grade 
3–5 complications and TPA at L4 superior for grade 3–5 
complications).
Of the potential confounders that were assessed for an 
association with overall postoperative complications, age 
and operation time were also associated with radiation 
attenuation and taken into account in the multivariate 
analysis for postoperative complications. In the final mul-
tivariate model (Table 2), lower skeletal muscle radiation 
attenuation was associated with an increased risk of over-
all postoperative complications (OR 0.91; 95% CI 0.85–
0.97; p = 0.003), as was young age (OR 0.92; 95% CI 0.87–
0.98; p = 0.007). 
For postoperative grade 3–5 (severe) complications, 
TPA at L4 superior and radiation attenuation, as well 
as  the potential confounders sex, Charlson comorbidi-
ty score, CEA before chemoradiation, and pathological 
T (ypT) stage were included in the multivariate analysis. 
A lower radiation attenuation (OR 0.89; 95% CI 0.83–
0.96; p = 0.002) and a higher total psoas mass at L4 supe-
rior (OR 1.46; 95% CI 1.10–1.94; p = 0.009) were associ-
ated with an increased risk of grade 3–5 complications 
(Table 2). 
Postoperative Morbidity and Sarcopenia
In the univariate analysis, sarcopenia was not signifi-
cantly associated with overall and grade 3–5 postopera-
tive complications. Sarcopenia measured as TPA at L4 
superior was the only variable with p < 0.150 that seemed 
Table 1. Univariate relation between skeletal muscle mass, radiation attenuation, and postoperative (grade 3–5) complicationsa
Postoperative complication Grade 3–5 postoperative complication
yes (n = 68) no (n = 31) pb value yes (n = 25) no (n = 74) pb value
L3
TPA 5.3±1.6 (n = 65) 5.5±1.7 (n = 31) 0.610 5.8±1.4 (n = 23) 5.3±1.6 (n = 73) 0.167
TAMA 47.1±9.0 (n = 65) 48.5±10.8 (n = 31) 0.516 49.0±9.4 (n = 23) 47.1±9.4 (n = 73) 0.406
Radiation attenuationc 34.8±8.7 (n = 67) 39.3±8.3 (n = 31) 0.018 32.3±8.4 (n = 24) 37.5±8.6 (n = 74) 0.010
L4 superior
TPA 7.2±1.9 (n = 65) 7.5±2.4 (n = 30) 0.514 7.9±1.8 (n = 23) 7.1±2.1 (n = 72) 0.099
TAMA 48.5±9.1 (n = 65) 49.5±10.9 (n = 30) 0.641 50.1±9.2 (n = 23) 48.4±9.8 (n = 72) 0.466
Radiation attenuationc 35.1±8.8 (n = 67) 39.2±8.0 (n = 30) 0.032 32.4±8.6 (n = 24) 37.6±8.5 (n = 73) 0.011
L4 inferior
TPA 7.8±2.2 (n = 64) 8.2±2.6 (n = 29) 0.531 8.6±2.0 (n = 22) 7.7±2.4 (n = 71) 0.105
TAMA 46.9±9.0 (n = 64) 47.8±11.1 (n = 29) 0.688 48.2±9.7 (n = 22) 46.9±9.7 (n = 71) 0.565
Radiation attenuationc 34.7±8.6 (n = 66) 40.6±12.8 (n = 29) 0.009 32.4±9.0 (n = 23) 37.8±10.5 (n = 72) 0.029
a Data are presented as mean ± SD. 
b Bold entries are significant (p < 0.05). 
c Radiation attenuation was measured as the mean HU of the total abdominal muscle area at the level of the third lumbar vertebra.
TPA, total psoas area in cm2∙m–2; TAMA, total abdominal muscle area in cm2∙m–2; HU, Hounsfield unit.
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to be associated with grade 3–5 complications. However, 
in the multivariate model, this association was not statis-
tically significant (OR 0.51; 95% CI 0.20–1.29; p = 0.152).
Postoperative Morbidity and Sarcopenic Obesity
In the univariate analysis, sarcopenic obesity was not 
significantly associated with overall complications. 
However, sarcopenic obesity when measured at TPA L4 
superior, TAMA L3 and TAMA L4 superior were associ-
ated with overall complications with p < 0.150 and were 
therefore included in 3 separate multivariate analyses, 
together with confounders (age and operation time). In 
the final multivariate models, sarcopenic obesity mea-
sured at TPA L4 superior, TAMA L3, and TAMA L4 
superior, and young age were significantly associated 
with postoperative complications (all p < 0.05; Table 3). 
Patients with sarcopenic obesity were 3 times more like-
ly (ORs between 3.2 and 3.8) to develop a postoperative 
complication.
No significant relation was found between sarcopenic 
obesity and grade 3–5 (severe) complications.
Overall Survival and Sarcopenia
In the univariate analysis, sarcopenia at TAMA L4 infe-
rior was the only variable that was associated with overall 
survival with a p < 0.150 (HR 2.04; 95% CI 0.83–4.99; p = 
Table 2. Univariate and multivariate relation between skeletal muscle mass, radiation attenuation, and postoperative (grade 3–5) com-
plicationsa
OR univariate
(95% CI)
p univariate OR multivariate
(95% CI)
p multivariate
Postoperative complications
Radiation attenuationb 0.94 (0.89–0.99) 0.021 0.91 (0.85–0.97) 0.003
Age, years 0.95 (0.90–1.00) 0.063 0.92 (0.87–0.98) 0.007
Operation time, min 1.01(1.00–1.02) 0.098 – –
Grade 3-5 complications
TPA L4 superior 1.20 (0.96–1.51) 0.103 1.46 (1.10–1.94) 0.009
Radiation attenuationb 0.93 (0.88–0.99) 0.013 0.89 (0.83–0.96) 0.002
Gender
Female
Male
Ref.
2.87 (1.07–7.67) 0.036
– –
Charlson comorbidity score
0
>1
Ref.
2.49 (0.98–6.36) 0.056
– –
CEA before CRT 0.98 (0.93–1.02) 0.318 – –
ypT stage
ypT0–1
ypT2–4
Ref.
0.43 (0.17–1.09) 0.076
– –
a Blood transfusion was not taken into account as a confounder in the multivariate analysis, since the necessity of intra- or postop-
erative blood transfusion could be an intermediary factor between skeletal muscle mass and postoperative complications.
b Radiation attenuation was measured as the mean HU of the total abdominal muscle area at the level of the third lumbar vertebra.
No value means that the confounder was removed from the equation because it did not significantly predict complications in the 
multivariate model.
TPA, total psoas area in cm2∙m–2; CEA, carcinoembryonic antigen; CRT, chemoradiation; ypT, pathological T stage; HU, Houns-
field unit.
Table 3. Multivariate relation between sarcopenic obesity and 
postoperative complications
OR 95% CI p value
L3
TAMA 3.77 1.12–12.66 0.032
Age, years 0.94 0.89–0.99 0.030
L4 superior
TPA 3.21 1.05–9.77 0.040
Age, years 0.94 0.90–1.00 0.033
L4 superior
TAMA 3.42 1.02–11.42 0.046
Age, years 0.94 0.90–1.00 0.034
TAMA, total abdominal muscle area in cm2∙m–2; TPA, total 
psoas area in cm2∙m–2.
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0.120). Of all baseline characteristics (see the Method sec-
tion) that were assessed for an association with overall sur-
vival, ASA, BMI, and tumor regression were also associated 
with sarcopenia at TAMA L4 inferior (p < 0.150) and taken 
into account in the multivariate analysis for overall surviv-
al. In the multivariate model, controlled for ASA, BMI, and 
tumor regression, none of the potential confounders re-
mained in the multivariate model after the stepwise regres-
sion. Therefore, the association between sarcopenia at 
TAMA L4 inferior and survival remained the same. 
Overall Survival and Sarcopenic Obesity
No significant relation was found between sarcopenic 
obesity and survival with p > 0.337.
Discussion
This retrospective study found that a lower skeletal 
muscle radiation attenuation was associated with overall 
and grade 3–5 (severe) postoperative morbidity after 
chemoradiation and resection for rectal cancer. Sarcope-
nic obesity was associated with overall complications. A 
few previous studies investigated the influence of skeletal 
muscle radiation attenuation on postoperative complica-
tions following colorectal cancer resection. Sabel et al. 
[22] showed that lower radiation attenuation was the best 
predictor of any complication after colectomy for colon 
cancer. Boer et al. [20] showed that lower radiation at-
tenuation was associated with overall complications after 
open colon resection for cancer. Body composition might 
be of key interest to use in predicting outcomes.
More studies investigated the role of sarcopenia on 
complications after colorectal surgery. Sarcopenia was as-
sociated with more infectious complications [5], higher 
mortality [18], and decreased survival [23] after colorectal 
cancer resection. Reisinger et al. [24] evaluated whether low 
muscle mass was associated with increased inflammation 
after resection of colorectal malignancies by measuring in-
flammatory markers in plasma. They found that a low mus-
cle mass was associated with an increased postoperative in-
flammatory response, which may be a part of the explana-
tion for the high incidence of postoperative complications 
in sarcopenic patients [24]. In the present study, no signif-
icant relation between sarcopenia and postoperative com-
plications was found. Sarcopenia is more than only a low 
skeletal muscle mass measured at a single time point. Sar-
copenia is characterized by the loss of skeletal muscle mass, 
skeletal muscle strength, and/or physical performance 
[25]. Defining sarcopenia only in terms of muscle mass 
might be too narrow and may therefore be of limited clini-
cal value [25]. An example is the finding in the present 
study that patients with a higher muscle mass (TPA at L4 
superior) more often had a grade 3–5 complication. Muscle 
mass might be not depleted in cross-sectional area because 
of more fat infiltration of the muscle. Fat infiltration is the 
most widely accepted cause of reduced attenuation of mus-
cle [26]. Measurement of radiation attenuation is poten-
tially a better approach. Future research should investigate 
if muscle strength measurements of a muscle biopsy (rectus 
abdominis muscle) correlate with CT measurements. 
Sarcopenic obesity could be of higher clinical use than 
sarcopenia alone. In the present study, sarcopenic obesity 
was associated with overall complications. Previously, 
sarcopenic obesity was found to be a predictor for grade 
3–5 postoperative complications following open colon 
cancer surgery [20], and an independent predictor of sur-
vival in patients with solid tumors in the respiratory or 
gastrointestinal tract [7]. After hepatic resection for 
colorectal liver metastasis, patients with sarcopenic obe-
sity had a more pronounced risk of severe complications 
compared with patients without sarcopenia (sarcopenic 
obesity 40% versus non-sarcopenia 8%, p = 0.02) [8]. 
Visser et al. [27] showed that sarcopenic obesity indepen-
dently increased the risk of postoperative infections in 
patients undergoing cardiac surgery. 
The current study underscores the importance of as-
sessing skeletal muscle mass and quality measurements to 
select high-risk patients that might benefit from preop-
erative optimization (prehabilitation) to prevent a dismal 
course. Studies show that high-risk patients who were 
placed on a physical exercise training program before ma-
jor elective surgery, improve their physical fitness [28–
30], even after [31] or during [10] neoadjuvant chemora-
diation in patients with rectal cancer. It remains to be 
seen, however, whether improving physical fitness in-
creases skeletal muscle mass, and vice versa. Currently, in 
our hospital, we perform a randomized controlled trial 
(www.trialregister.nl, trial registration number NTR4032) 
to measure the effect of a 3-week prehabilitation program 
on postoperative complications in high-risk patients who 
are to undergo colorectal surgery [32], all in accordance 
with a part of the recent advises of Hulzebos and Van 
Meeteren [9]. In this trial, the effect of the prehabilitation 
program on muscle strength will also be investigated.
Since undergoing a CT scan is part of usual care in the 
work up of all patients with rectal cancer, no additional test 
is needed to evaluate skeletal muscle mass and radiation 
attenuation. Skeletal muscle mass and radiation attenua-
tion measurements could potentially be used as a case-mix 
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correction factor in the Dutch Surgical Colorectal Audit 
(DSCA), a quality registration of colorectal surgery in the 
Netherlands, to make a more accurate comparison of out-
come among various hospitals. Future research should re-
veal optimal skeletal muscle index and quality cutoff points 
in this specific population. Moreover, it would be of inter-
est to investigate the association between skeletal muscle 
measurements and oncological outcome and prognosis. 
Our study has some limitations. Definitions of sarco-
penia and sarcopenic obesity remain under debate. We 
used definitions based on previous studies [20, 21], 
which are different than those used in several other stud-
ies. A different definition could have led to different re-
sults. Moreover, the univariate associations between 
muscle mass index and outcome, as well as between 
muscle radiation attenuation and outcome were not cal-
culated for males and females separately, while body 
composition is not the same between sexes. We used 
BMI for the definition of sarcopenic obesity based on 
previous research [7]; however, adipose tissue measure-
ments on the CT scan might be superior to the calcula-
tion of BMI. The explorative nature of the skeletal mus-
cle mass analyses at 3 different levels might be both a 
limitation as well as a strength of our study. For future 
research, using level L3 might be recommended [33]. 
But, it remains to be seen whether or not using L3 CT-
slices is the best approach. Due to the retrospective and 
explorative nature of this study, and the limited number 
of patients, it is subject to potential bias and certain lim-
itations with respect to their internal validity and gener-
alization. Our findings should therefore be interpreted 
with caution. More research is needed to confirm our 
results. Since surgery took place between 2007 and 2012, 
no laparoscopic procedures were performed. Nowadays, 
to follow a laparoscopic approach is more common and 
known to result in less complications [34], but the re-
sults here may of course only account for non-laparo-
scopic surgical approaches. 
Conclusion
In this explorative manuscript, we found that skeletal 
muscle radiation attenuation was associated with overall 
and grade 3–5 (severe) postoperative morbidity after 
chemoradiation and non-laparoscopic resection for rectal 
cancer. Sarcopenic obesity was associated with overall com-
plications. Skeletal muscle mass and sarcopenia were not 
associated with postoperative complications. Body compo-
sition might be used to identify patients with high risk of 
worse outcome after surgery, paving the way to select pa-
tients that might benefit from preoperative optimization.
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